Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
Sammy Huygens, Bas B. Oude Munnink, Arvind Gharbharan, Marion Koopmans, Bart Rijnders
Abstract
Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.
Topics & Concepts
MedicinePersistence (discontinuity)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Viral replicationRespiratory systemCoronavirusCoronavirus disease 2019 (COVID-19)ImmunologyVirus2019-20 coronavirus outbreakInternal medicineDiseaseGeotechnical engineeringInfectious disease (medical specialty)EngineeringOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses